FDA Approval Alert: The Need-to-Know | Encorafenib/Cetuximab/mFOLFOX6 in Advanced BRAF V600E+ CRC

In December 2024, the FDA granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer harboring a BRAF V600E mutation.

FDA
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
Article
Dec 20, 2024 6:38 PM
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.